Switch theme
Sign up to access all valuation multiples
Yifeng Pharmacy Chain Co Ltd is mainly engaged in the chain retail business of medicines, health products, medical devices and health-related daily convenience products.
2008
n/a
LTM Revenue $3.5B
LTM EBITDA $375M
$4.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yifeng Pharmacy has a last 12-month revenue of $3.5B and a last 12-month EBITDA of $375M.
In the most recent fiscal year, Yifeng Pharmacy achieved revenue of $3.1B and an EBITDA of $530M.
Yifeng Pharmacy expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yifeng Pharmacy valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.1B | $3.4B | XXX | XXX | XXX |
| Gross Profit | $852M | $1.1B | XXX | XXX | XXX |
| Gross Margin | 27% | 32% | XXX | XXX | XXX |
| EBITDA | $530M | $355M | XXX | XXX | XXX |
| EBITDA Margin | 17% | 10% | XXX | XXX | XXX |
| Net Profit | $122M | $174M | XXX | XXX | XXX |
| Net Margin | 4% | 5% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Yifeng Pharmacy's stock price is CNY 28 (or $4).
Yifeng Pharmacy has current market cap of CNY 34.3B (or $4.7B), and EV of CNY 31.8B (or $4.4B).
See Yifeng Pharmacy trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.4B | $4.7B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Yifeng Pharmacy has market cap of $4.7B and EV of $4.4B.
Yifeng Pharmacy's trades at 1.2x LTM EV/Revenue multiple, and 11.7x LTM EBITDA.
Analysts estimate Yifeng Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Yifeng Pharmacy and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.4B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.3x | XXX | XXX | XXX |
| P/E | 21.7x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 21.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpYifeng Pharmacy's NTM/LTM revenue growth is 13%
Yifeng Pharmacy's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Yifeng Pharmacy's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Yifeng Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Yifeng Pharmacy and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yifeng Pharmacy acquired XXX companies to date.
Last acquisition by Yifeng Pharmacy was XXXXXXXX, XXXXX XXXXX XXXXXX . Yifeng Pharmacy acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Yifeng Pharmacy founded? | Yifeng Pharmacy was founded in 2008. |
| Where is Yifeng Pharmacy headquartered? | Yifeng Pharmacy is headquartered in China. |
| Is Yifeng Pharmacy publicy listed? | Yes, Yifeng Pharmacy is a public company listed on SHG. |
| What is the stock symbol of Yifeng Pharmacy? | Yifeng Pharmacy trades under 603939 ticker. |
| When did Yifeng Pharmacy go public? | Yifeng Pharmacy went public in 2015. |
| Who are competitors of Yifeng Pharmacy? | Similar companies to Yifeng Pharmacy include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Yifeng Pharmacy? | Yifeng Pharmacy's current market cap is $4.7B |
| What is the current revenue of Yifeng Pharmacy? | Yifeng Pharmacy's last 12-month revenue is $3.5B. |
| What is the current EBITDA of Yifeng Pharmacy? | Yifeng Pharmacy's last 12-month EBITDA is $375M. |
| What is the current EV/Revenue multiple of Yifeng Pharmacy? | Current revenue multiple of Yifeng Pharmacy is 1.2x. |
| What is the current EV/EBITDA multiple of Yifeng Pharmacy? | Current EBITDA multiple of Yifeng Pharmacy is 11.7x. |
| What is the current revenue growth of Yifeng Pharmacy? | Yifeng Pharmacy revenue growth between 2023 and 2024 was 9%. |
| Is Yifeng Pharmacy profitable? | Yes, Yifeng Pharmacy is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
